Lenalidomide-Related Diarrhea in Patients with Multiple Myeloma Is Associated with Gut Microbiota Dysbiosis and Disruption of the Bile Acid Pool.

Clin Cancer ResOct 1, 2026
Clinical ResearchHematologyGastroenterology

Kevin Charles Miller, Teng Fei, Ruben J Faustino Ramos et al.

✦ AI-curated · Sources linked

In 30 seconds

This Phase II randomized controlled trial investigated the relationship between gut microbiota dysbiosis, bile acid pool disruption, and lenalidomide-related diarrhea (LRD) in patients with multiple myeloma. The study found that patients with LRD exhibited increased fecal bile acid abundance and reduced microbiota diversity, suggesting that microbiota alterations may contribute to LRD risk.

Key findings

  • Patients with LRD had increased fecal bile acid abundance and reduced α-diversity.
  • LRD samples showed altered community composition and reduced predicted bile acid-processing capacity.
  • Baseline microbiota and bile acid profiles differed in patients who developed LRD.

Why it matters

Understanding the mechanisms behind lenalidomide-related diarrhea can help clinicians identify at-risk patients and explore microbiota-targeted interventions to improve patient quality of life during treatment.

Source

PubMed · PMID 42474437

Published in Clin Cancer Res. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Hematology

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.